Medical
First Australian study on cardiovascular impact of COVID-19 at The Alfred
Medical News: While some international evidence suggests the infectious virus can leave behind cardiac scarring, cardiologists and respiratory physicians are working together to explore whether unexplained breathlessness may be the first sign of trouble.
The Alfred’s director of cardiology Professor David Kaye, and cardiologist Dr Shane Nanayakkara, have spent years studying pressure levels inside the hearts of patients as part of research into a condition known as heart failure with preserved ejection fraction (HFpEF).
In HFpEF, the heart muscle becomes stiff and doesn’t fill properly, leading to increased pressure and shortness of breath. Together with respiratory physician Professor Trevor Williams, Professor Kaye and his team are looking for the same signs of damage in those who have had COVID-19.
“While the international evidence has been mixed, it’s possible that some patients sustain cardiac damage from COVID-19 infection,” Prof Kaye said.
“Similar to HFpEF, one of the ways of we can measure changes in the heart is to perform catheter testing during exercise.”
After inserting a slim catheter into the body via a patient’s arm, they are asked to lie on a bed that has bike pedals attached. Dr Nanayakkara said the team then observes the pressures inside the heart as the patient exercises.
“If the pressures go up abnormally, that’s a warning sign, and then we can explore further and, hopefully, offer treatment,” Dr Nanayakkara said.
“We still have a lot to learn about the mark COVID can leave on the heart, but we encourage anyone who experiences unexplained and prolonged breathlessness after the virus to ask their GP for a referral to come and see us in the Heart Centre at The Alfred.”
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More